HIKMA (MAPLE) LIMITED – Trademark Portfolio
Entity Type: 03
HIKMA (MAPLE) LIMITED holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. Currently, 4 trademarks are registered. Notable registered marks include DOPRAM, FACTREL, DURAMORPH, and INFUMORPH. The owner is based in LONDON.
13 HANOVER SQUARE
LONDON W1S 1HL , GB
Showing of trademarks Trademarks
Trademark Classifications
HIKMA (MAPLE) LIMITED's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does HIKMA (MAPLE) LIMITED have?
HIKMA (MAPLE) LIMITED has 7 U.S. trademarks filed with the USPTO. Of these, 4 registered, 3 cancelled.
What trademark classes does HIKMA (MAPLE) LIMITED file in?
HIKMA (MAPLE) LIMITED files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are HIKMA (MAPLE) LIMITED's most well-known trademarks?
HIKMA (MAPLE) LIMITED's registered trademark portfolio includes well-known marks such as DOPRAM, FACTREL, DURAMORPH, and INFUMORPH. These are among 4 currently registered trademarks in the portfolio.
What is HIKMA (MAPLE) LIMITED's trademark registration success rate?
HIKMA (MAPLE) LIMITED has a 57% trademark registration rate, with 4 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.